Carlon Colker

Early life

Colker was born to parents of Russian Jewish and Lithuanian descent. Both of them were artists. His father, Edward Colker, was a graduate of New York University, a noted lithographer, a maker of rare hand-bound books, and a Guggenheim Fellowship recipient. His mother, Elaine Galen, was a graduate of the University of Pennsylvania and an abstract painter. As a child, Colker grew up around the diversity of his parent’s art world while being exposed to their penchant for healthy living, organic foods, and vitamin supplements.

Education

Colker received a baccalaureate degree in June 1988 from Manhattanville College in Purchase, New York. He received his medical degree in May 1993 from Sackler School of Medicine. From 1993 to 1996, he received residency training in internal medicine at Beth Israel Medical Center in Manhattan, New York.

Professional

In 1996, Colker was employed first at Park Avenue Medical Nutrition and then later that year, by Affiliated Physicians, both located in New York City. In January 1996 he established Peak Wellness, Inc., a company with locations in Greenwich, Connecticut and Beverly Hills, California that provides integrative medical services. Colker is an affiliate of Greenwich Hospital in Greenwich, Connecticut. and is an attending physician in the Department of Medicine at Mount Sinai Beth Israel Hospital in New York City. Colker also serves as a voluntary faculty member (clinical assistant professor of medicine in neurology) at Weill Cornell Medical College in New York City.

In February 2011, Colker served as chief medical officer and executive vice president of Atlas Therapeutics Corp. (OTCBB: ATTH; formerly Marvin's Place, Inc.; dba MYOS Corp. as of May 2012; OTCBB:MYOS). In June 2012, Colker resigned his position and became a member of the company's scientific advisory board. In 2008, it was announced that Colker would be serving on the advisory board of the supplement manufacturing company LifeVantage. In 2005, Colker was named as head of the scientific advisory board of the dietary supplement manufacturer Health Sciences Group, Inc. (OTCBB:HESG), and in 2006 the company announced that Colker would be assisting in the formulation of the supplement product Sequestrol. Colker was also a product developer and spokesperson for the dietary supplement Lipistat, marketed by ITV Ventures. He has served as a spokesperson, adviser, product developer, and/or researcher for the supplement companies Cytodyne Technologies, Inc., Muscletech Research and Development, Metabolife International, Inc., and Vital Basics, Inc. Colker has also served as a Health and Nutrition Consultant for Fairway Market, an American grocery chain.

Ephedra

Colker has generated controversy regarding his public comments and research on the safety of ephedra-based dietary supplements. Colker was the lead researcher responsible for studies and product development on behalf of supplement manufacturers such as Cytodyne Technologies, Inc., Muscletech Research and Development, and Metabolife International, Inc., manufacturers of the ephedra-based weight loss pills Xenadrine RFA-1, Hydroxycut, and Metabolife 365, respectively.

Following the February 2003 heatstroke-related death of Baltimore Orioles pitcher Steve Bechler, in which ephedra was implicated as the cause, Colker and two other physicians, all speaking on behalf of the industry-affiliated Ephedra Education Council, disputed the role that ephedra played in Bechler’s death. Colker also downplayed the dangers of ephedra, claiming that it "is not a health risk for most people".

In May 2003, a California Superior Court judge handed down a $12.5 million judgment in a class action suit against Cytodyne Technologies for falsely advertising Xenadrine RFA-1, the product implicated in the death of Bechler. Colker had been enlisted by Cytodyne to conduct a clinical study on the effectiveness of Xenadrine RFA-1, and upon the study’s completion, the company paid Colker approximately $5,000 to field calls from customers and make conference appearances. Referring to Colker's research, the judge noted that Colker lacked credibility and concluded that Cytodyne had "not just exaggerated the findings of the clinical trials it commissioned, but had also cajoled some researchers into fudging results", and that those involved in the research on Xenadrine RFA-1 had set out "to create a study that justified the money being spent by Cytodyne and that would ensure that they received further work from the company". Journalists for the New York Times commenting on Cytodyne's research noted that the legal case raised "serious questions about the way makers of ephedra and other dietary supplements use -- and often misuse -- the promise of scientific proof to market their products".

During 2003, Colker was named as a defendant in lawsuits filed in Missouri, West Virginia, and Illinois in connection with his involvement in the research and marketing of Hydroxycut and Xenadrine RFA-1. The lawsuits alleged that Colker and his Greenwich clinic, Peak Wellness Inc., ran fraudulent tests, altered test results, and hid dangerous adverse reactions suffered by test subjects. In July 2003, Colker was called to testify before a United States House Committee on Energy and Commerce investigating deaths and adverse events stemming from ephedra supplements for which Colker had been involved in researching and marketing.

V-Factor

Colker previously served as a researcher and television spokesperson for “V-Factor” (a combination of yohimbine, L-arginine, and Gingko biloba), a dietary supplement marketed by Vital Basics, Inc. of Portland, Maine as a men’s sexual performance enhancer. In 2004, the U.S. Federal Trade Commission registered a complaint against Vital Basics and its owners alleging, in part, that the company’s advertising of V-Factor violated Federal law; specifically, that the company made unsubstantiated claims about V-Factor’s safety; falsely represented that a clinical study of V-Factor conducted by Colker proved that the product was safe and effective; and misrepresented paid commercial advertising featuring Colker (Vital Basics Health Show radio infomercials) as independent radio programs. The defendants settled the FTC’s complaint by paying $1 million for consumer redress and agreeing not to make unsubstantiated claims in the future.

MYO-X/MYO-T12

In January 2015, Entertainment Tonight reported that entertainer Justin Bieber had credited Colker with recommending MYO-X, a dietary supplement that Bieber had allegedly used in preparation for a Calvin Klein underwear photo shoot. Bieber was criticized for “…hyping Colker’s latest “miracle” supplement MYO-X, to his 59 million Twitter fans.”

SEC documents filed by the manufacturer (MYOS Corp.; dba Atlas Therapeutics until May 2012), indicate that the product consists of a powder isolated from the yolk of fertilized chicken eggs. It was developed by Colker in 2005 as a supplement formulation that was marketed initially under the trade name Folstaxan by Celldyne Biopharma LLC and, subsequently, under the trade name MYO-T12 by Atlas/MYOS. The product was implied to contain follistatin and to increase muscle mass by inhibiting myostatin.

In February 2011, Colker sold the marketing rights and trademarks for MYO-T12 to MYOS for $1.15 million and entered into a three-year employment agreement to serve as the company’s Chief Medical Officer and Executive vice-president, resigning in 2012 to serve as a scientific advisor for the company in exchange for 300,000 shares of common stock. Under the terms of licensing agreements with MYOS, MYO-T12 is distributed by Maximum Human Performance (MHP) under the brand name MYO-X, and by Cenegenics (NASDAQ:CELG) under the brand name Cenegenics Muscle Formula (Fortetropin).

Myostatin inhibitors are specifically banned by the World Anti-Doping Agency (WADA). In an August 12, 2012 interview with National Public Radio, Colker stated “when the myostatin inhibitors come along, they'll be abused. There's no question in my mind.”

Jeremy Piven and mercury poisoning

In December 2008, actor Jeremy Piven announced that he would be withdrawing from the lead role as Bobby Gould in David Mamet’s Broadway play Speed-the-Plow. Piven, who had previously sought an early release from the production, cited mercury poisoning from eating sushi and taking herbal supplements as the reason for his decision to leave the show prematurely. Colker, who said that Piven had come to him soon after the show had opened and complained of excessive fatigue and exhaustion, was responsible for making the diagnosis and providing Piven with medical advice that “he should end his run immediately.” According to a letter sent by Colker to the show’s producers, he stressed that “it’s important to underscore that” withdrawing from the play was not Piven’s decision and said “it was my decision.” Writers for the magazine Variety and Gawker expressed skepticism about the legitimacy of Piven’s excuse for withdrawing from the play, and Mamet wryly commented “my understanding is that he is leaving show business to pursue a career as a thermometer.” The producers of the show pursued grievance and arbitration hearings through the Actors Equity union. The arbitrator in the dispute, George Nicolau, ruled in Pevin’s favor in August 2009. Commenting on the ruling, producer Jeffrey Richards stated “while we were disappointed with the arbitrator’s decision, we accept it and have put the matter behind us.”

Media appearances

Colker appeared as a guest physician and trainer on the ABC reality TV program Shaq's Big Challenge.

In 2008 Colker promoted the inaugural National Family Fitness Day. Colker appeared in the 2008 movie Bigger, Stronger, Faster. and narrated the 2010 documentary short film LUNCH, which investigated the causes and consequences of children growing up in a junk-food culture.

Books